Engineering nanomaterials for nanomedicine evolution: Progress, trends and translational challenges

Nanomedicine, enabled by advances in engineered nanomaterials, has reshaped modern healthcare by providing more precise and effective therapy, diagnosis, and disease monitoring. This review surveys current trends across major classes of nanomaterials, including organic platforms (liposomes, polymeric nanoparticles, dendrimers), inorganic systems (gold, silica, iron oxide), carbon-based nanostructures (graphene derivatives and nanotubes), and hybrid composites. We highlight transformative applications spanning cancer therapy, high-sensitivity diagnostics, infectious disease control, regenerative medicine, nano-vaccines, and diabetes management. We further examine the accelerating integration of artificial intelligence (AI) and machine learning (ML), which are revolutionizing nanoparticle design, biological interaction prediction, and drug discovery by replacing inefficient trial-and-error workflows. Despite remarkable progress, clinical translation remains hindered by unresolved challenges in nano-toxicology, standardized characterization, scalable manufacturing, regulatory harmonization, and ethical and socioeconomic equity. We argue that sustained interdisciplinary collaboration, robust safety frameworks, and green, patient-centric design are essential to translate laboratory innovation into equitable, affordable, and clinically impactful nanomedicines. Looking ahead, the convergence of AI-driven nanoparticle design, bio-hybrid systems, and sustainable nano-manufacturing will define the next era of precision medicine, enabling integrated diagnosis and treatment as well as personalized interventions that address longstanding limitations in modern healthcare.